1. Jubierre L, Jiménez C, Rovira E, Soriano A, Sábado C, Gros L, et al. Targeting of epigenetic regulators in neuroblastoma. Exp Mol Med. 2018; 50:51. PMID:
29700278.
2. Rickman DS, Schulte JH, Eilers M. The expanding world of N-MYC-driven tumors. Cancer Discov. 2018; 8:150–163. PMID:
29358508.
3. Meena JP, Gupta AK. Neuroblastoma in a developing country: miles to go. Indian J Pediatr. 2019; 86:403–405. PMID:
30915646.
4. Zareifar S, Shakibazad N, Zekavat OR, Bordbar M, Shahriari M. Successful treatment of refractory metastatic neuroblastoma with panobinostat in combination with chemotherapy agents and iodine-131-meta-iodobenzylguanidine therapy. J Oncol Pharm Pract. 2020; 26:481–486. PMID:
31156056.
5. Herd F, Basta NO, McNally RJQ, Tweddle DA. A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma. Eur J Cancer. 2019; 111:50–58. PMID:
30822684.
6. Swift CC, Eklund MJ, Kraveka JM, Alazraki AL. Updates in diagnosis, management, and treatment of neuroblastoma. Radiographics. 2018; 38:566–580. PMID:
29528815.
7. PDQ Pediatric Treatment Editorial Board. Neuroblastoma Treatment (PDQ®): Health Professional Version. PDQ Cancer Information Summaries. Bethesda (MD): National Cancer Institute (US);2002.
8. Valter K, Zhivotovsky B, Gogvadze V. Cell death-based treatment of neuroblastoma. Cell Death Dis. 2018; 9:113. PMID:
29371588.
9. Pastor ER, Mousa SA. Current management of neuroblastoma and future direction. Crit Rev Oncol Hematol. 2019; 138:38–43. PMID:
31092383.
10. Han Y, Ye X, Cheng J, Zhang S, Feng W, Han Z, et al. Integrative analysis based on survival associated co-expression gene modules for predicting Neuroblastoma patients' survival time. Biol Direct. 2019; 14:4. PMID:
30760313.
11. Yao W, Li K, Dong KR, Zheng S, Xiao XM. Long-term prognosis of low-risk neuroblastoma treated by surgery alone: an experience from a single institution of China. World J Pediatr. 2019; 15:148–152. PMID:
30446974.
12. Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015; 33:3008–3017. PMID:
26304901.
13. Morgenstern DA, Bagatell R, Cohn SL, Hogarty MD, Maris JM, Moreno L, et al. The challenge of defining “ultra-high-risk” neuroblastoma. Pediatr Blood Cancer. 2019; 66:e27556. PMID:
30479064.
14. Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, et al. Revisions to the international neuroblastoma response criteria: a consensus statement from the National Cancer Institute clinical trials planning meeting. J Clin Oncol. 2017; 35:2580–2587. PMID:
28471719.
15. Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, et al. Neuroblastoma. Nat Rev Dis Primers. 2016; 2:16078. PMID:
27830764.
16. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009; 27:289–297. PMID:
19047291.
17. Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993; 11:1466–1477. PMID:
8336186.
18. Hu CY, Pan ZY, Yang J, Chu XH, Zhang J, Tao XJ, et al. Nomograms for predicting long-term overall survival and cancer-specific survival in lip squamous cell carcinoma: a population-based study. Cancer Med. 2019; 8:4032–4042. PMID:
31112373.
19. Liu G, Liu Q, Sun SR. Nomograms for estimating survival in patients with papillary thyroid cancer after surgery. Cancer Manag Res. 2019; 11:3535–3544. PMID:
31114382.
20. Huang L, Balavarca Y, van der Geest L, Lemmens V, Van Eycken L, De Schutter H, et al. Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a large international population-based cohort study. BMC Med. 2019; 17:66. PMID:
30905320.
21. Guo CX, Shen YN, Zhang Q, Zhang XZ, Wang JL, Gao SL, et al. Prediction of postoperative pancreatic fistula using a nomogram based on the updated definition. Ann Surg Treat Res. 2020; 98:72–81. PMID:
32051815.
22. Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019; 17:479–505. PMID:
31085757.
23. Xie Y, Xu H, Fang F, Li Z, Zhou H, Pan J, et al. A 3-protein expression signature of neuroblastoma for outcome prediction. Am J Surg Pathol. 2018; 42:1027–1035. PMID:
29794872.
24. Li X, Meng Y. A prognostic nomogram for neuroblastoma in children. PeerJ. 2019; 7:e7316. PMID:
31338261.
25. Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med. 1997; 16:385–395. PMID:
9044528.
26. Hu J, Wang T, Zhang KH, Jiang YP, Xu S, Chen SH, et al. Pretreatment risk management of a novel nomogram model for prediction of thoracoabdominal extrahepatic metastasis in primary hepatic carcinoma. J Transl Med. 2019; 17:117. PMID:
30961629.
27. Jiang Y, Wang W, Chen C, Zhang X, Zha X, Lv W, et al. Radiomics signature on computed tomography imaging: association with lymph node metastasis in patients with gastric cancer. Front Oncol. 2019; 9:340. PMID:
31106158.
28. London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, et al. Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol. 2011; 29:3286–3292. PMID:
21768459.
29. Louis CU, Shohet JM. Neuroblastoma: molecular pathogenesis and therapy. Annu Rev Med. 2015; 66:49–63. PMID:
25386934.